We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04439695
Recruitment Status : Completed
First Posted : June 19, 2020
Last Update Posted : September 16, 2021
Information provided by (Responsible Party):
KBio Inc

Brief Summary:
This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.

Condition or disease Intervention/treatment Phase
Influenza Biological: Low dose Biological: Intermediate dose Biological: High dose Biological: Placebo Phase 1

Detailed Description:

Subjects will be screened up to 14 days (Day -14 to Day 0) before randomization.

On the planned day of vaccination (Day 1), subjects will be randomized in a 1:1:1:1 ratio (N = 30 subjects/group) to receive study vaccine or placebo by intramuscular (IM) injection.

Approximately 5 subjects per group (N = 20) will be enrolled in parallel initially, and safety data through Day 8 will be collected. An Independent Data Monitoring Committee (IDMC) will convene to review Day 8 safety data before any additional subjects will be enrolled. If there are no safety concerns in the IDMC meeting, study enrollment will continue.

Blood and serum samples for safety laboratory tests and HAI titers will be obtained at baseline on Day 1 before administration of vaccine dose and after vaccination.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
Actual Study Start Date : June 25, 2020
Actual Primary Completion Date : February 25, 2021
Actual Study Completion Date : July 28, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot Vaccines

Arm Intervention/treatment
Experimental: Low Dose KBP-V001
Subjects in this group will receive the low dose of KBP-V001.
Biological: Low dose
Low dose of KBP-V001

Experimental: Intermediate KBP-V001
Subjects in this group will receive the intermediate dose of KBP-V001.
Biological: Intermediate dose
Intermediate dose of KBP-V001

Experimental: High Dose KBP-V001
Subjects in this group will receive the high dose of KBP-V001.
Biological: High dose
High dose of KBP-V001

Placebo Comparator: Placebo
Subjects in this group will receive placebo
Biological: Placebo
Buffered Saline Solution

Primary Outcome Measures :
  1. Solicited administration site reactions [ Time Frame: 7 days after vaccination ]
    Occurrences of Adverse Events

  2. Solicited systemic events [ Time Frame: 7 days after vaccination ]
    Occurrences of Adverse Events

Secondary Outcome Measures :
  1. Number of Unsolicited Adverse Events [ Time Frame: 43 days after vaccination ]
    Safety Endpoint

  2. Number of Serious Adverse Events and Medically Attended Events [ Time Frame: 181 days after vaccination ]
    Safety Endpoint

  3. Vaccine HAI antibody Titers [ Time Frame: Day 1, 29, 43, 181 ]
    Vaccine HAI antibody Titers for each treatment group

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  1. Have read, understood, and signed the informed consent form (ICF)
  2. Healthy adult males and females ages 18 to 49 years, inclusive at screening
  3. Body mass index (BMI) of ≥18 and ≤34 kg/m2 at screening
  4. Must be in general good health before study participation with no clinically relevant abnormalities that could interfere with study assessments
  5. Women of childbearing potential (WOCBP) and men whose sexual partners are WOCBP must be able and willing to use at least 1 highly effective method of contraception during the study and for 3 months after the study completion. A female subject is considered to be a WOCBP after menarche and until she is in a postmenopausal state for 12 consecutive months (without an alternative medical cause) or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
  6. Female subjects of childbearing potential must have a negative urine pregnancy test before vaccination
  7. Must be able to attend all visits for the duration of the study and comply with all study procedures, including completion of Diary Card according to the study schedule.

Exclusion Criteria

  1. History of an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses.
  2. History of ongoing clinical condition or medication or treatments that may adversely affect the immune system.
  3. Individuals with any elevated (Grade 2 or higher) laboratory test assessed as clinically significant by investigator at screening
  4. Individuals with any elevated (Grade 2 or higher) liver function enzyme at screening, regardless of the appraisal of clinical significance (cannot be retested to qualify for study). See below the criteria for excluding subjects with elevated liver enzymes:

    • Alanine aminotransferase (ALT)/aspartate aminotransferase (AST): >3 × upper limit of normal (ULN)
    • Total bilirubin: >2 × ULN
    • Alkaline phosphatase (ALP)/gamma-glutamyl transferase (GGT): >2.5 × ULN
  5. Active neoplastic disease (excluding nonmelanoma skin cancer that was successfully treated) or a history of any hematological malignancy. For this criterion, "active" is defined as having received treatment within the past 5 years.
  6. Long-term (greater than 2 weeks) use of oral or parenteral steroids or high-dose inhaled steroids (>800 μg/day of beclomethasone dipropionate or equivalent) within 6 months before screening (nasal and topical steroids are allowed)
  7. History of autoimmune or inflammatory disease
  8. Women currently pregnant, nursing, or planning a pregnancy between enrollment and 181 days after randomization
  9. History of a previous serious adverse reaction to any influenza vaccine
  10. History of Guillain-Barré Syndrome
  11. History of anaphylactic-type reaction to injected vaccines
  12. Known or suspected hypersensitivity to 1 or more of the components of TAP-V001
  13. History of illicit drug use or alcohol abuse in the year before screening
  14. Receipt of any influenza vaccine within 6 months before screening
  15. Receipt of any vaccine within 1 month before screening
  16. Acute illness or fever within 3 days before study enrollment (enrollment may be delayed for full recovery if acceptable to the investigator)
  17. Individuals currently participating or planning to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, or medication); or who have received an experimental agent within 1 month before enrollment in this study; or who expect to receive another experimental agent during participation in this study; or who intend to donate blood during the study period.
  18. Receipt of immunoglobulin or another blood product within the 3 months before enrollment in this study or those who expect to receive immunoglobulin or another blood product during this study.
  19. Individuals who plan to receive another vaccine, including seasonal influenza vaccine, during the entire 6-month study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04439695

Layout table for location information
United States, Nebraska
Meridian Clinical Research
Omaha, Nebraska, United States, 68134
Sponsors and Collaborators
KBio Inc
Layout table for investigator information
Study Director: Hugh Haydon Kentucky BioProcessing
Principal Investigator: Brandon Essink, MD Meridian Clinical Research
Layout table for additonal information
Responsible Party: KBio Inc
ClinicalTrials.gov Identifier: NCT04439695    
Other Study ID Numbers: KBP-101
First Posted: June 19, 2020    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Plan is to share study data by dosing group in publications

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by KBio Inc:
Influenza Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases